Clinical Report: Alterations in Circulating Damage-Associated Molecular Patterns in Patients with Diabetic Foot Syndrome
Overview
This study identifies systemic alterations in circulating damage-associated molecular patterns (DAMPs) in patients with diabetic foot syndrome (DFS).
Background
Diabetic foot syndrome is a significant complication of diabetes, leading to increased amputation rates and severe infections. Understanding the molecular mechanisms underlying DFS is crucial for developing effective interventions. This study explores the role of DAMPs in the inflammatory processes associated with DFS.
Data Highlights
Proteomic analysis revealed differences in the abundance of multiple proteins associated with inflammation and stress in DFS patients compared to diabetic controls.
Key Findings
Identified proteins include serum amyloid A1, S100A8, and fibrinogen chains, which differ in abundance between DFS patients and controls.
Several DAMPs exhibited reproducible patterns across the studied groups, indicating a coordinated molecular response.
TLR4 inhibition in a murine model altered the abundance of circulating proteins, suggesting a link between innate immune signaling and DAMP profiles.
Findings support the hypothesis of systemic alterations in DAMP abundance in DFS.
Proteomics data are available via ProteomeXchange with identifier PXD073507.
Clinical Implications
The identification of specific DAMPs associated with DFS may guide future research.
Conclusion
The study provides evidence of systemic DAMP alterations in patients with diabetic foot syndrome.
by Elena Uyy, Viorel-Iulian Suica, Luminita Ivan, Raluca Maria Boteanu, Diana Valentina Uta, Elena Georgiana Bernea, Dragoş Eugen Georgescu, Ovidiu Chiriac, Maya Simionescu, Felicia Antohe
Age-related macular degeneration (AMD) is among the most common retinal diagnoses. Although the clinical features of the disease are well known, ICD-10 coding can be confusing if details such as stage, activity, and laterality are not clearly documented. Incomplete documentation may prompt questions about the medical necessity of diagnostic tests or intravitreal injections. This Q&A addresses common sources of confusion and offers practical guidance to support clear, accurate documentation.
